[go: up one dir, main page]

CL2007003465A1 - Pharmaceutical combination of at least two active uv-absorbent substances, where one of them is at least a pyrrolotriazine compound; and its use to treat unwanted skin conditions, such as polymorphic light eruption, actinic keratosis, among others. - Google Patents

Pharmaceutical combination of at least two active uv-absorbent substances, where one of them is at least a pyrrolotriazine compound; and its use to treat unwanted skin conditions, such as polymorphic light eruption, actinic keratosis, among others.

Info

Publication number
CL2007003465A1
CL2007003465A1 CL2007003465A CL2007003465A CL2007003465A1 CL 2007003465 A1 CL2007003465 A1 CL 2007003465A1 CL 2007003465 A CL2007003465 A CL 2007003465A CL 2007003465 A CL2007003465 A CL 2007003465A CL 2007003465 A1 CL2007003465 A1 CL 2007003465A1
Authority
CL
Chile
Prior art keywords
active
pharmaceutical combination
skin conditions
actinic keratosis
unwanted skin
Prior art date
Application number
CL2007003465A
Other languages
Spanish (es)
Inventor
Alonso Oscar Jimenez
Arjona Jordi Corbera
Cabanas Carlos Ramon Trullas
Costa David Panyella
Olga Capa
Original Assignee
Isdin Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isdin Sa filed Critical Isdin Sa
Publication of CL2007003465A1 publication Critical patent/CL2007003465A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4966—Triazines or their condensed derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52—Stabilizers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/59—Mixtures
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/59—Mixtures
    • A61K2800/592—Mixtures of compounds complementing their respective functions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Combinación farmacéutica de al menos dos sustancias activasuv-absorbentes, donde una de ellas es al menos un compuesto de pirrolotriazina; y su uso para tratar condiciones cutáneas no deseadas, tales como, erupción lumínica polimórfica, queratosis actínica, entre otras.Pharmaceutical combination of at least two active uv-absorbent substances, where one of them is at least one pyrrolotriazine compound; and its use to treat unwanted skin conditions, such as polymorphic light eruption, actinic keratosis, among others.

CL2007003465A 2006-12-04 2007-11-30 Pharmaceutical combination of at least two active uv-absorbent substances, where one of them is at least a pyrrolotriazine compound; and its use to treat unwanted skin conditions, such as polymorphic light eruption, actinic keratosis, among others. CL2007003465A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06025059 2006-12-04

Publications (1)

Publication Number Publication Date
CL2007003465A1 true CL2007003465A1 (en) 2009-03-27

Family

ID=37946487

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2007003465A CL2007003465A1 (en) 2006-12-04 2007-11-30 Pharmaceutical combination of at least two active uv-absorbent substances, where one of them is at least a pyrrolotriazine compound; and its use to treat unwanted skin conditions, such as polymorphic light eruption, actinic keratosis, among others.

Country Status (4)

Country Link
AR (1) AR064132A1 (en)
CL (1) CL2007003465A1 (en)
PE (1) PE20081198A1 (en)
WO (1) WO2008067928A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2322159A1 (en) 2009-10-30 2011-05-18 Green Molecular, S.L. Use of pterostilbene (pter) as medicament for prevention and/or treatment of skin diseases, damages or injures or as cosmetic
BE1019432A3 (en) * 2010-07-23 2012-07-03 Auriga Internat USE OF ISOTHIOCYANATES AND DERIVATIVES FOR THE TREATMENT AND / OR PREVENTION OF LUCITES.
CN102993439A (en) * 2012-10-30 2013-03-27 无锡三幸高膜科技有限公司 Water-soluble polytriazine macromolecular material
CN107057125A (en) * 2017-05-18 2017-08-18 句容亿格纳米材料厂 Modified salicylic acid aligns the preparation and its application in anti-light pollution plastics of octyl phenyl ester

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3581002D1 (en) * 1984-06-22 1991-02-07 Ilford Ag HYDROXYPHENYLTRIAZINE, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS A UV ABSORBER.
DE19543730A1 (en) * 1995-11-23 1997-05-28 Ciba Geigy Ag Until resorcinyl-triazines
CN100528847C (en) * 2002-03-12 2009-08-19 西巴特殊化学品控股有限公司 Uv absorber compositions comprising a hydroxyphenyltriazine compound
JP4671953B2 (en) * 2003-01-20 2011-04-20 チバ ホールディング インコーポレーテッド Triazine derivatives as UV absorbers
ES2264624B1 (en) * 2004-12-16 2007-11-01 Isdin, S.A. NEW DERIVATIVES OF TRIAZINE, AS WELL AS PROCEDURES FOR THEIR OBTAINING AND ITS USE AS PROTECTIVE AGENTS AGAINST UV RADIATION.

Also Published As

Publication number Publication date
WO2008067928A1 (en) 2008-06-12
PE20081198A1 (en) 2008-09-18
AR064132A1 (en) 2009-03-11

Similar Documents

Publication Publication Date Title
ECSP088402A (en) COMPOUNDS AND COMPOSITIONS CONTAINING DIARILAMINE, AND ITS USE AS MODULATORS OF C-KIT RECEIVERS
ECSP077275A (en) NOVEDOSOS DERIVED FROM HETEROARILSULFAMIDA BENZOFUSIONADOS USEFUL AS ANTICONVULSIVE AGENTS
BRPI0721905B8 (en) Proteasome inhibitor compound, its pharmaceutical composition and its use
CL2009001032A1 (en) Combinations of active compounds to control animal pests; use of combinations; and procedures to control animal pests.
CL2008000593A1 (en) USE OF COMPOUNDS DERIVED FROM REPLACED HETEROCICLES; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS AND OTHER ACTIVE AGENTS; AND ITS USE TO TREAT DIABETES, ATEROSCLEROTIC DISEASE OF ARTERIES BETWEEN OTHER DISEASES.
EA201390184A1 (en) ACTIVATING AMRK HETEROCYCLIC COMPOUNDS AND METHODS FOR THEIR USE
ECSP088904A (en) ARILIMIDAZOLONAS AND ARILTRIAZOLONAS REPLACED AS INHIBITORS OF VASOPRESINE RECEPTORS
CL2011000544A1 (en) Compounds derived from benzamide n substituted by heterocycle, cannabinoid receptor ligands; pharmaceutical composition; and its use to treat pain, among other diseases.
BRPI0608604B8 (en) indoleamine 2,3-dioxygenase modulators and pharmaceutical composition
CL2008002319A1 (en) Compounds derived from pyrrolopyrimidine; pharmaceutical composition comprising said compounds; and its use to treat cancer.
AR047928A1 (en) TETRAHYDROPIRIDOINDOL DERIVATIVES
DOP2013000130A (en) PIRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS THROUGH LP - PLA2
CU20140072A7 (en) DERIVATIVES OF DIHIDRO-OXAZINA AND DIHIDRO-PIRIDO-OXAZINA
EA201070169A1 (en) 2,3-DIHYDROBENZO [1,4] DIOXIN-2-ILMETHYL DERIVATIVES AS AN ALPHA2S ANTAGONISTS FOR THE APPLICATION IN THE TREATMENT OF DISEASES OF THE CIRCULAR NERVOUS SYSTEM
ECSP088884A (en) FUSIONED HETEROCICLICAL COMPOUNDS AND THEIR USE AS MODULATORS OF MGLUR5
CL2007002971A1 (en) COMPOUNDS DERIVED FROM AMINOMETIL-4-IMIDAZOL; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM; AND ITS USE TO TREAT DEPRESSION, ANXIETY, BIPOLAR DISORDER, AMONG OTHERS.
NI200800176A (en) USE OF BENZO-FUSED HETEROCYCLIC SULFAMID DERIVATIVES FOR THE TREATMENT OF DEPRESSION
CL2009001298A1 (en) Compounds derived from n-cyclohexyl-2-phenoxynicotinamide; pharmaceutical composition comprising them; pharmaceutical combination comprising them; and its use to treat a disease mediated by pde4.
EA201001288A1 (en) TREATMENT OF HYPERTENSION WITH 25-HYDROXIVITAMIN D3
UY30918A1 (en) MODULATORS OF LTA4H AND ITS USES
EA201170979A1 (en) CARBOXAMIDE COMPOUNDS AND METHODS OF THEIR APPLICATION
CL2011002160A1 (en) Compounds derived from substituted 3-amino-2-mercaptoquinolines; pharmaceutical composition containing said compounds; and its use to treat pain, epilepsy, urinary incontinence, manias, migraine, bipolar disorders, cognitive diseases, dyskinesia associated with dystonia and / or urinary incontinence.
CL2011000341A1 (en) Compounds derived from substituted pyrrolidinone, modulators of ar activity for the inhibition of ntd; preparation procedure; pharmaceutical composition; and use for the treatment of cancer, acne, hirsutism, among others.
CL2007002970A1 (en) COMPOUNDS DERIVED FROM AMINOMETIL-4-IMIDAZOL; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM; AND ITS USE TO TREAT DEPRESSION, ANXIETY, BIPOLAR DISORDER, AMONG OTHERS.
CL2008002084A1 (en) Compounds derived from benzenesulfonyl chroman, thiochroman, tetrahydronaphthalene, gamma secretase inhibitors; pharmaceutical composition comprising it; and its use in the preparation of useful drugs to treat neurodegenerative diseases